Glenmark Life Sciences Ltd. (ALIVUS) Share Price Hits New 52-Week High

Glenmark Life Sciences Ltd. Share Price has reached a new 52-week high, closing at Rs 1,360, a 2.19% increase from the previous close of Rs 1,330.8. The stock opened at Rs 1,332 and peaked at Rs 1,361.95 during the day. With a market capitalisation of Rs 16,338.42 crore, the company is attracting significant investor attention. This fresh 52-week high highlights the stock's current momentum in the market.

Glenmark Life Sciences Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,360
Previous Close	Rs 1,330.8
Today's Change	+Rs 29.2 (+2.19%)
Day Open	Rs 1,332
Fresh 52-Week High	Rs 1,361.95
Day Low	Rs 1,327.85
Current Volume	3,600
Turnover	Rs 0.49 crore
Market Capitalisation	Rs 16,338.42 crore

Glenmark Life Sciences Ltd. (ALIVUS) traded at Rs 1,360. versus the previous close of Rs 1,330.8, a rise of 2.19%. The stock opened at Rs 1,332, reached Rs 1,361.95, touched Rs 1,327.85. Reported volume was 3,600.

Today, Glenmark Life Sciences Ltd. Share Price opened at Rs 1,332 and reached a high of Rs 1,361.95, setting a new 52-week high. The stock closed at Rs 1,360, marking a Rs 29.2 increase or 2.19% rise from the previous close of Rs 1,330.8. The day's low was Rs 1,327.85, with a turnover of Rs 0.49 crore and a volume of 3,600 shares. This price action indicates strong investor interest and market activity.

Glenmark Life Sciences Ltd. (ALIVUS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 16,338.42 crore
P/E Ratio	31.4x
P/B Ratio	0.46x
ROE	-2.89%
ROCE	-0.26%

Glenmark Life Sciences Ltd. was valued at a P/E ratio of 31.4x, a P/B ratio of 0.46x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	31.4x
Benchmark Median P/E	21.61x
Benchmark Average P/E	72.01x
Benchmark P/E Range	0x to 3,428.55x
Company P/B Ratio	0.46x
Benchmark Median P/B	1.92x
Company ROE	-2.89%
Benchmark Median ROE	10.75%
Company ROCE	-0.26%
Benchmark Median ROCE	13.29%
Company Market Capitalisation	Rs 16,338.42 crore
Benchmark Median Market Cap	Rs 139.72 crore

Glenmark Life Sciences Ltd. (ALIVUS) is classified under sector: Healthcare.

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 31.4x, which is above the benchmark median of 21.61x, a difference of +45.3%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Glenmark Life Sciences Ltd. (ALIVUS) has a ROE of -2.89%, which is below the benchmark median of 10.75%, a difference of -126.88%. Glenmark Life Sciences Ltd. (ALIVUS) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,943.6	31.4	0.46	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,684.11	39.39	8.02	28.21	26.35
Beta Drugs Ltd.	BETA	2,621.81	63.25	10.01	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,511.89	32.96	6.79	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,347.02	160.63	2.97	13.9	12.97

Glenmark Life Sciences Ltd. (ALIVUS) has a P/E ratio of 31.4x compared with the displayed peer median of 39.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Glenmark Life Sciences Ltd. (ALIVUS) has a market capitalisation of Rs 16,338.42 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching Glenmark Life Sciences Ltd.

• Glenmark Life Sciences Ltd. Share Price reached a new 52-week high, indicating strong market momentum.
• The company operates in the Healthcare sector, which has a wide valuation range.
• Despite a high P/E ratio, profitability metrics are currently negative.
• Market cap is significantly higher than some peers, suggesting a strong market position.

About Glenmark Life Sciences Ltd.

Glenmark Life Sciences Ltd. is a prominent player in the Healthcare sector, focusing on the development and manufacture of active pharmaceutical ingredients (APIs). The company serves a global clientele, providing high-quality APIs for various therapeutic areas. Its operations are supported by advanced manufacturing facilities and a commitment to innovation, positioning it as a key contributor to the pharmaceutical supply chain.

Track Glenmark Life Sciences Ltd. Share Price on Univest

Use Glenmark Life Sciences Ltd. (ALIVUS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track Glenmark Life Sciences Ltd. Share Price, technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest for comprehensive analysis and informed decision-making.

Frequently Asked Questions

What is the current share price of Glenmark Life Sciences Ltd.?

Ans. The current share price of Glenmark Life Sciences Ltd. is Rs 1,360, marking a 2.19% increase from the previous close. The stock moved 2.19% during the session. The intraday range extended from Rs 1,327.85 to Rs 1,361.95.

What is the market capitalisation of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a market capitalisation of Rs 16,338.42 crore, reflecting its size and market position. The company operates in the Healthcare sector. Its P/E ratio is 31.4x.

How does Glenmark Life Sciences Ltd.'s P/E ratio compare to the sector?

Ans. Glenmark Life Sciences Ltd.'s P/E ratio of 31.4 is above the sector median of 21.61 but below the average of 72.01. The company trades at a P/E ratio of 31.4x.

What are the profitability metrics of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, indicating challenges in profitability. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.75%.

What is the 52-week high of Glenmark Life Sciences Ltd.?

Ans. The 52-week high of Glenmark Life Sciences Ltd. is Rs 1,361.95, achieved recently. The stock moved 2.19% during the session. The intraday range extended from Rs 1,327.85 to Rs 1,361.95.

How does Glenmark Life Sciences Ltd.'s market cap compare to its peers?

Ans. Glenmark Life Sciences Ltd.'s market cap of Rs 16,338.42 crore is significantly higher than some peers like Dishman Carbogen Amcis Ltd. The company operates in the Healthcare sector. Its P/E ratio is 31.4x.

What is the P/B ratio of Glenmark Life Sciences Ltd.?

Ans. Glenmark Life Sciences Ltd. has a P/B ratio of 0.46, indicating its market value relative to its book value. The company trades at a P/E ratio of 31.4x. Its P/B ratio is 0.46x.

Where can I track Glenmark Life Sciences Ltd. Share Price?

Ans. You can track Glenmark Life Sciences Ltd. Share Price and other financial metrics on Univest for comprehensive insights. The stock moved 2.19% during the session. The intraday range extended from Rs 1,327.85 to Rs 1,361.95.